Glaukos Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
1,094
- Stock Symbol
-
GKOS
- Investments
-
5
- Share Price
-
$238.10
- (As of Thursday Closing)
Glaukos General Information
Description
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Contact Information
Website
www.glaukos.comCorporate Office
- One Glaukos Way
- Aliso Viejo, CA 92656
- United States
Corporate Office
- One Glaukos Way
- Aliso Viejo, CA 92656
- United States
Glaukos Stock Performance
As of 19-Nov-2026, Glaukos’s stock price is $238.10. Its current market cap is $14.1B with 59.2M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $238.10 | $233.08 | $93.78 - $255.19 | $14.1B | 59.2M | 1.18M | -$2.94 |
Glaukos Financials Summary
As of 30-Sep-2026, Glaukos has a trailing 12-month revenue of $690M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 9,501,183 | 6,315,559 | 8,161,960 | 3,962,008 |
| Revenue | 690,332 | 507,442 | 383,481 | 314,711 |
| EBITDA | (133,130) | (156,776) | (106,744) | (91,280) |
| Net Income | (169,799) | (187,691) | (146,372) | (134,661) |
| Total Assets | 979,529 | 893,487 | 974,756 | 940,414 |
| Total Debt | 101,983 | 103,876 | 103,399 | 383,738 |
Glaukos Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Glaukos Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Glaukos Comparisons
Industry
Financing
Details
Glaukos Competitors (19)
One of Glaukos’s 19 competitors is Sight Sciences, a Formerly VC-backed company based in Menlo Park, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sight Sciences | Formerly VC-backed | Menlo Park, CA | ||||
| Apollo Endosurgery | Formerly VC-backed | Austin, TX | ||||
| Tivic Health Systems | Formerly VC-backed | Hayward, CA | ||||
| Nova Eye Medical | Corporation | Kent Town, Australia | ||||
| BVI Medical | Private Equity-Backed | Waltham, MA |
Glaukos Patents
Glaukos Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-252402-S | Drug eluting ocular implant | Active | 26-Feb-2025 | ||
| WO-2026177996-A1 | Methods and systems for transferring viscous fluid to containers | Pending | 19-Feb-2025 | ||
| US-20260174681-A1 | Drug formulations and ocular implants having the same | Pending | 20-Dec-2024 | ||
| WO-2026136907-A1 | Drug formulations and ocular implants having the same | Pending | 20-Dec-2024 | ||
| WO-2026050299-A1 | Drug delivery implants as intraocular drug depots | Pending | 27-Aug-2024 | A61F9/0017 |
Glaukos Signals
Glaukos Investments & Acquisitions (5)
Glaukos’s most recent deal was a Merger/Acquisition with Mobius Therapeutics for . The deal was made on 16-May-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Mobius Therapeutics | 16-May-2025 | Merger/Acquisition | Pharmaceuticals | ||
| Avedro | 21-Nov-2019 | Merger/Acquisition | Pharmaceuticals | ||
| DOSE Medical | 27-Jun-2019 | Merger/Acquisition | Drug Delivery | ||
| DOSE Medical (IOP sensor system assets and related liabilities) | 12-Apr-2017 | Corporate Asset Purchase | Buildings and Property | ||
| DOSE Medical (iDose product line) | 30-Jun-2015 | Corporate Asset Purchase | Buildings and Property |
Glaukos ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
22.43 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Glaukos Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Mobius Therapeutics | Saint Louis, MO | 2006 |
Glaukos FAQs
-
When was Glaukos founded?
Glaukos was founded in 1998.
-
Where is Glaukos headquartered?
Glaukos is headquartered in Aliso Viejo, CA.
-
What is the size of Glaukos?
Glaukos has 1,094 total employees.
-
What industry is Glaukos in?
Glaukos’s primary industry is Surgical Devices.
-
Is Glaukos a private or public company?
Glaukos is a Public company.
-
What is Glaukos’s stock symbol?
The ticker symbol for Glaukos is GKOS.
-
What is the current stock price of Glaukos?
As of 19-Nov-2026 the stock price of Glaukos is $238.10.
-
What is the current market cap of Glaukos?
The current market capitalization of Glaukos is $14.1B.
-
What is Glaukos’s current revenue?
The trailing twelve month revenue for Glaukos is $690M.
-
Who are Glaukos’s competitors?
Sight Sciences, Apollo Endosurgery, Tivic Health Systems, Nova Eye Medical, and BVI Medical are some of the 19 competitors of Glaukos.
-
What is Glaukos’s annual earnings per share (EPS)?
Glaukos’s EPS for 12 months was -$2.94.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process